Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide

Anti-Cancer Drugs

Volumn 15, Issue 8, 2004, Pages 779-785

  Hour, Tzyh Chyuan ^a   Huang, Chao Yuan ^b   Lin, Chia Chi ^c   Chen, Jun ^b   Guan, Jing Yi ^b   Lee, Jen Mei ^a   Pu, Yeong Shiau ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arsenicals; DNA repair; Drug resistance; p53; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; ARSENICALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FORECASTING; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; MUTS HOMOLOG 2 PROTEIN; NF-KAPPA B; OXIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 4644320306     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200409000-00007     Document Type: Article

References (30)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
2. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88:1052-1061.
3. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91:772-776.
4. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
5. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, et al. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 1999; 4:33-37.
6. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6: 4957-4964.
7. Barrett MP, Fairlamb AH. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol Today 1999; 15: 136-140.
8. Rossman TG, Goncharova EI, Rajah T, Wang Z. Human cells lack the inducible tolerance to arsenite seen in hamster cells. Mutat Res 1997; 386:307-314.
9. Lee TC, Ho IC. Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect 1994; 102(suppl 3):101-105.
10. Yu HJ, Tsai TC, Hsieh TS, Chiu TY. Characterization of a newly established human bladder carcinoma cell line, NTUB1. J Formosan Med Ass 1992; 91:608-613.
11. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
12. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59:253-276.
13. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Hsieh CY, et al. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 2000; 20:3221-3225.
14. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 2002; 51:211-218.
15. waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas. Cancer Res 2001; 61: 3157-3163.
16. Arango D, Corner GA, Wadler S, Catalane PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001; 61:4910-4915.
17. Pu YS, Tsai TC, Cheng AL, Tsai CY, Tseng NF, Su IJ, et al. Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J Urol 1996; 156:271-275.
18. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999; 455:59-62.
19. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology 2002; 60:346-350.
20. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997; 76:206-210.
21. Fishel R, Wilson T. MutS homologs in mammalian cells. Curr Opin Genet Dev 1997; 7:105-113.
22. Okui T, Fujiwara Y. Inhibition of human excision DNA repair by inorganic arsenic and the co-mutagenic effect in V79 Chinese hamster cells. Mutat Res 1986; 172:69-76.
23. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996; 3:579-589.
24. Matsui M, Nishigori C, Toyokuni S, Takada J, Akaboshi M, Ishikawa M, et al. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol 1999; 113:26-31.
25. Romach EH, Zhao CQ, Del Razo LM, Cebrian ME, Waalkes MP. Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol Sci 2000; 54:500-508.
26. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 2002; 13:293-300.
27. de Martin R, Schmid JA, Hofer-Warbinek R. The NF-kappaB/Rel family of transcription factors in oncogenic transformation and apoptosis. Mutat Res 1999; 437:231-243.
28. Hsu SC, Gavrilin MA, Lee HH, Wu CC, Han SH, Lai MZ. NF-kappa B-dependent Fas ligand expression. Eur J Immunol 1999; 29:2948-2956.
29. Sohur US, Chen CL, Hicks DJ, Yull FE, Kerr LD. Nuclear factor-kappaB/Rel is apoptogenic in cytokine withdrawal-induced programmed cell death. Cancer Res 2000; 60:1202-1205.
30. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13:382-387.